GSK's Licensor Hansoh Pharma Announces Positive Results From a Second Phase III Trial for Ris-Rez in China
July 29, 2026
July 29, 2026
LONDON, England, July 29 -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release on July 28, 2026:
* * *
GSK's licensor Hansoh Pharma announces positive results from a second phase III trial for Ris-Rez in China
* ARTEMIS-011, a phase III study conducted for China, met its primary endpoint of progression-free survival in relapsed osteosarcoma
* Results add to a growing body of positive late-stage e . . .
* * *
GSK's licensor Hansoh Pharma announces positive results from a second phase III trial for Ris-Rez in China
* ARTEMIS-011, a phase III study conducted for China, met its primary endpoint of progression-free survival in relapsed osteosarcoma
* Results add to a growing body of positive late-stage e . . .